Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galunisertib + capecitabine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Galunisertib + capecitabine is a combination therapy being investigated for the treatment of advanced chemotherapy-resistant colorectal cancer, particularly in patients with peritoneal metastases. Galunisertib is an oral small molecule TGFβR1 inhibitor that targets the TGF-β signaling pathway, which is implicated in drug resistance in colorectal cancer. Capecitabine is an oral fluoropyrimidine chemotherapy agent that is converted to 5-fluorouracil in the body. The combination aims to overcome resistance to 5-FU-based chemotherapy, especially in the mesenchymal subtype of colorectal cancer (CMS4) which has elevated TGF-β signaling causing drug resistance against multiple anticancer drugs.
- Brand names
- Xeloda
- Other names
- galunisertib plus capecitabineLY2157299 + capecitabineMoTriColor
02
Targets
TGFBR1TS (Thymidylate synthase)
Beyond the preview
Go deeper on galunisertib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galunisertib + capecitabine.